This Article Full Text Full Text (PDF) Erratum (v19,p2109) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Leventis, A. K. Articles by Slawin, K. M. Search for Related Content PubMed PubMed Citation Articles by Leventis, A. K. Articles by Slawin, K. M.

Prediction of Response to Salvage Radiation Therapy in Patients With Prostate Cancer Recurrence After Radical Prostatectomy

From the Matsunaga-Conte Prostate Cancer Research Center, Scott Department of Urology, and Departments of Radiation Oncology and Pathology, Baylor College of Medicine, and Methodist Hospital, Houston, TX; and Department of Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY.

Address reprint requests to Kevin M. Slawin, MD, Scott Department of Urology, Baylor Prostate Center, Baylor College of Medicine, 6560 Fannin, Ste 2100, Houston, TX 77030; email: kslawin{at}bcm.tmc.edu

PURPOSE: To identify factors predictive of local recurrence as defined by a complete response to salvage radiation therapy in patients whose disease recurs after radical prostatectomy.

PATIENTS AND METHODS: Ninety-five patients with recurrence after radical prostatectomy who were evaluated by prostatic fossa biopsies, and a subset of 49 of these patients treated with radiation for control of presumed or biopsy-proven local recurrence, were studied.

RESULTS: Biopsies were positive in 40 (42%) of the 95 biopsied patients. Multivariate analysis revealed that prebiopsy prostate-specific antigen (PSA) level, postrecurrence PSA doubling time, and positive digital rectal examination (DRE) of the prostatic fossa were all statistically significant predictors of a positive biopsy. For the 49 patients subsequently treated with salvage radiation therapy, the overall actuarial 3- and 5-year PSA relapse-free probabilities were 43% and 24%, respectively. Univariate analysis showed no differences in the PSA relapse-free probabilities associated with any pathologic features of the radical prostatectomy specimen, biopsy confirmation of local recurrence, or DRE of the prostatic fossa. In multivariate analysis, controlling for all other variables, preradiation PSA and postrecurrence PSA doubling time measured before radiation were the only statistically significant predictors of outcome.

CONCLUSION: DRE of the prostatic fossa, prebiopsy PSA, and postrecurrence PSA doubling time predict which patients will have biopsy-proven local recurrence. However, response to salvage radiation therapy is associated with postrecurrence PSA doubling time and with preradiation PSA level only. DRE of the prostatic fossa and biopsy confirmation of local recurrence are not associated with salvage radiation outcome.

This article has been cited by other articles:

				B. J. Trock, M. Han, S. J. Freedland, E. B. Humphreys, T. L. DeWeese, A. W. Partin, and P. C. Walsh Prostate Cancer-Specific Survival Following Salvage Radiotherapy vs Observation in Men With Biochemical Recurrence After Radical Prostatectomy JAMA, June 18, 2008; 299(23): 2760 - 2769. [Abstract] [Full Text] [PDF]

				S. F. Shariat, J. A. Karam, J. Walz, C. G. Roehrborn, F. Montorsi, V. Margulis, F. Saad, K. M. Slawin, and P. I. Karakiewicz Improved Prediction of Disease Relapse after Radical Prostatectomy through a Panel of Preoperative Blood-Based Biomarkers Clin. Cancer Res., June 15, 2008; 14(12): 3785 - 3791. [Abstract] [Full Text] [PDF]

				S. F. Shariat, K. Bensalah, J. A. Karam, C. G. Roehrborn, A. Gallina, Y. Lotan, K. M. Slawin, and P. I. Karakiewicz Preoperative Plasma HER2 and Epidermal Growth Factor Receptor for Staging and Prognostication in Patients with Clinically Localized Prostate Cancer Clin. Cancer Res., September 15, 2007; 13(18): 5377 - 5384. [Abstract] [Full Text] [PDF]

				O. Riesterer, L. Milas, and K. K. Ang Use of Molecular Biomarkers for Predicting the Response to Radiotherapy With or Without Chemotherapy J. Clin. Oncol., September 10, 2007; 25(26): 4075 - 4083. [Abstract] [Full Text] [PDF]

				F. Shimizu, S. Tanaka, Y. Matsuyama, T. Tominaga, Y. Ohashi, and M. Fujime Efficiency of Ultrasensitive Prostate-specific Antigen Assay in Diagnosing Biochemical Failure After Radical Prostatectomy Jpn. J. Clin. Oncol., June 1, 2007; 37(6): 446 - 451. [Abstract] [Full Text] [PDF]

				A. J. Stephenson, P. T. Scardino, M. W. Kattan, T. M. Pisansky, K. M. Slawin, E. A. Klein, M. S. Anscher, J. M. Michalski, H. M. Sandler, D. W. Lin, et al. Predicting the Outcome of Salvage Radiation Therapy for Recurrent Prostate Cancer After Radical Prostatectomy J. Clin. Oncol., May 20, 2007; 25(15): 2035 - 2041. [Abstract] [Full Text] [PDF]

				A. K. Lee and A. V. D'Amico Utility of Prostate-Specific Antigen Kinetics in Addition to Clinical Factors in the Selection of Patients for Salvage Local Therapy J. Clin. Oncol., November 10, 2005; 23(32): 8192 - 8197. [Abstract] [Full Text] [PDF]

				S. B. Hayes and A. Pollack Parameters for Treatment Decisions for Salvage Radiation Therapy J. Clin. Oncol., November 10, 2005; 23(32): 8204 - 8211. [Abstract] [Full Text] [PDF]

				K. Numata, K. Azuma, K. Hashine, and Y. Sumiyoshi Predictor of Response to Salvage Radiotherapy in Patients with PSA Recurrence after Radical Prostatectomy: the Usefulness of PSA Doubling Time Jpn. J. Clin. Oncol., May 1, 2005; 35(5): 256 - 259. [Abstract] [Full Text] [PDF]

				A. J. Stephenson, S. F. Shariat, M. J. Zelefsky, M. W. Kattan, E. B. Butler, B. S. Teh, E. A. Klein, P. A. Kupelian, C. G. Roehrborn, D. A. Pistenmaa, et al. Salvage Radiotherapy for Recurrent Prostate Cancer After Radical Prostatectomy JAMA, March 17, 2004; 291(11): 1325 - 1332. [Abstract] [Full Text] [PDF]

				S. F. Shariat, M. W. Kattan, E. Traxel, B. Andrews, K. Zhu, T. M. Wheeler, and K. M. Slawin Association of Pre- and Postoperative Plasma Levels of Transforming Growth Factor {beta}1 and Interleukin 6 and Its Soluble Receptor with Prostate Cancer Progression Clin. Cancer Res., March 15, 2004; 10(6): 1992 - 1999. [Abstract] [Full Text] [PDF]

				H. I. Scher, M. Eisenberger, A. V. D'Amico, S. Halabi, E. J. Small, M. Morris, M. W. Kattan, M. Roach, P. Kantoff, K. J. Pienta, et al. Eligibility and Outcomes Reporting Guidelines for Clinical Trials for Patients in the State of a Rising Prostate-Specific Antigen: Recommendations From the Prostate-Specific Antigen Working Group J. Clin. Oncol., February 1, 2004; 22(3): 537 - 556. [Abstract] [Full Text] [PDF]

				S. F. Shariat, M. W. Kattan, W. Song, D. Bernard, E. Gottenger, T. M. Wheeler, and K. M. Slawin Early Postoperative Peripheral Blood Reverse Transcription PCR Assay for Prostate-specific Antigen Is Associated with Prostate Cancer Progression in Patients Undergoing Radical Prostatectomy Cancer Res., September 15, 2003; 63(18): 5874 - 5878. [Abstract] [Full Text] [PDF]

				C. T. Thomas, P. T. Bradshaw, B. H. Pollock, J. E. Montie, J. M.G. Taylor, H. D. Thames, P. W. McLaughlin, D. A. DeBiose, D. H. Hussey, and R. L. Wahl Indium-111-Capromab Pendetide Radioimmunoscintigraphy and Prognosis for Durable Biochemical Response to Salvage Radiation Therapy in Men After Failed Prostatectomy J. Clin. Oncol., May 1, 2003; 21(9): 1715 - 1721. [Abstract] [Full Text] [PDF]

				M. S. Katz, M. J. Zelefsky, E. S. Venkatraman, Z. Fuks, A. Hummer, and S. A. Leibel Predictors of Biochemical Outcome With Salvage Conformal Radiotherapy After Radical Prostatectomy for Prostate Cancer J. Clin. Oncol., February 1, 2003; 21(3): 483 - 489. [Abstract] [Full Text] [PDF]

				S. F. Shariat, E. Gottenger, C. Nguyen, W. Song, M. W. Kattan, J. Andenoro, T. M. Wheeler, D. M. Spencer, and K. M. Slawin Preoperative Blood Reverse Transcriptase-PCR Assays for Prostate-specific Antigen and Human Glandular Kallikrein for Prediction of Prostate Cancer Progression after Radical Prostatectomy Cancer Res., October 15, 2002; 62(20): 5974 - 5979. [Abstract] [Full Text] [PDF]

				S. F. Shariat, M. Shalev, A. Menesses-Diaz, I. Y. Kim, M. W. Kattan, T. M. Wheeler, and K. M. Slawin Preoperative Plasma Levels of Transforming Growth Factor Beta1 (TGF-{beta}1) Strongly Predict Progression in Patients Undergoing Radical Prostatectomy J. Clin. Oncol., June 1, 2001; 19(11): 2856 - 2864. [Abstract] [Full Text] [PDF]

				A. K. Leventis, S. F. Shariat, and K. M. Slawin Local Recurrence after Radical Prostatectomy: Correlation of US Features with Prostatic Fossa Biopsy Findings Radiology, May 1, 2001; 219(2): 432 - 439. [Abstract] [Full Text]